BAY 43-9006: early clinical data in patients with advanced solid malignancies
Related Experiment Video
Updated: Sep 29, 2026
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
Published on: May 24, 2024
Sebastien J Hotte1, Hal W Hirte
1Department of Medicine, McMaster University and Division of Medical Oncology, Hamilton Regional Cancer Centre, Ontario, Canada.
Abstract:
Various signalling pathways can confer the malignant phenotype to a cell. Ras signalling proteins have been found to play an important role in controlling cellular growth. Raf-1 is a protein kinase that exerts its effects downstream of Ras in the mitogen-activated protein kinase pathway and is thus likely to be crucial in the development of the malignant phenotype. BAY 43-9006 is an orally administered selective inhibitor of Raf-1 and the first compound of its class to enter clinical trials. This article describes the early clinical data of BAY 43-9006 in patients with advanced, refractory solid tumours. To date, over 60 patients have been treated as part of four Phase I clinical trials. Dose levels have ranged from 50mg once weekly to 200mg twice-daily in continuous administration. The drug has been generally well tolerated with no dose limiting toxicity yet encountered. The more common toxicities have involved the gastrointestinal tract (diarrhea, nausea, abdominal cramping) and the skin (pruritus, rash, cheilitis). Pharmacokinetic evaluations have found BAY 43-9006 to have considerable interpatient variability. However, there seems to be an increase in C(max) and AUC values with increasing dose. There is no clear effect of food on bioavailability. Splitting the dose to twice-daily administration has shown increases in C(max) and AUC values but is also accompanied by considerable interpatient variability.
Insights
BAY 43-9006, a Raf-1 inhibitor, shows early promise in treating advanced solid tumors. The drug is generally well-tolerated, with manageable side effects, and demonstrates dose-dependent pharmacokinetic profiles in Phase I trials.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Ras signaling pathways are crucial for cellular growth and the development of malignant phenotypes.
- Raf-1, a protein kinase downstream of Ras, plays a key role in the mitogen-activated protein kinase pathway.
- Malignant transformation involves complex signaling pathways, making targeted therapies essential.
Purpose of the Study:
- To describe the early clinical data of BAY 43-9006, a selective Raf-1 inhibitor.
- To evaluate the safety, tolerability, and pharmacokinetics of BAY 43-9006 in patients with advanced, refractory solid tumors.
- To assess the impact of different dosing regimens on drug exposure.
Main Methods:
- Phase I clinical trials involving over 60 patients with advanced, refractory solid tumors.
- Administration of BAY 43-9006 at various dose levels (50mg weekly to 200mg twice-daily).
- Monitoring of adverse events, pharmacokinetic parameters (Cmax, AUC), and bioavailability.
Main Results:
- BAY 43-9006 was generally well-tolerated with no dose-limiting toxicity observed.
- Common toxicities included gastrointestinal issues (diarrhea, nausea) and skin reactions (pruritus, rash).
- Pharmacokinetic evaluations revealed significant interpatient variability, with increased Cmax and AUC values at higher doses and with twice-daily administration.
Conclusions:
- BAY 43-9006 is a well-tolerated Raf-1 inhibitor with a manageable safety profile in patients with advanced solid tumors.
- The drug exhibits dose-dependent pharmacokinetics, suggesting potential for therapeutic efficacy.
- Further investigation in larger trials is warranted to confirm its clinical benefit.
Related Concept Videos
01:16Clinical Trials
There are four phases in a clinical trial. A phase one...
01:11Clinical Trials: Overview